Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for First Tracks Biotherapeutics's Debt-to-EBITDA or its related term are showing as below:
TRAX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.15 Med: -0.12 Max: -0.09
Current: -0.09
During the past 2 years, the highest Debt-to-EBITDA Ratio of First Tracks Biotherapeutics was -0.09. The lowest was -0.15. And the median was -0.12.
TRAX's Debt-to-EBITDA is ranked worse than 100% of 318
companies
in the Biotechnology industry
Industry Median: 1.27
vs TRAX: -0.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
First Tracks Biotherapeutics Debt-to-EBITDA Related Terms
First Tracks Biotherapeutics Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Debt-to-EBITDA Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
Debt-to-EBITDA
-0.15
-0.09
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
Debt-to-EBITDA
-0.15
-0.09
TRAX vs AVLN, IMTX, ARDX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Dec. 2024) EBITDA data.
First Tracks Biotherapeutics (TRAX) has a Debt-to-EBITDA of -0.09 as of Dec. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on First Tracks Biotherapeutics. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 318 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' Debt-to-EBITDA too high?
First Tracks Biotherapeutics' current Debt-to-EBITDA is -0.09. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 318 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Debt-to-EBITDA compare to AVLN and IMTX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 318 companies for Debt-to-EBITDA. This places First Tracks Biotherapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on First Tracks Biotherapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current Debt-to-EBITDA is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Debt-to-EBITDA of -0.09. The current Debt-to-EBITDA is -0.09. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Debt-to-EBITDA is -0.09 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score
Get the complete analysis for TRAX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRAX has been successfully added to your 
